Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a novel HER2-CAR monocyte cell therapy with controllable proliferation and enhanced anti-tumor efficacy

19 Jan 2024

Abstract excerpt

BACKGROUND: One of the significant challenges for cell therapies, such as chimeric antigen receptor (CAR)-T cell therapy, is the poor infiltration of immune cells into tumor tissues. CAR-monocytes/macrophages (CAR-M) are promising therapies because of their enrichment in the tumor microenvironment. Thus, we constructed a novel CAR-M to facilitate the infiltration of T cells and other immune cells. METHODS: The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune cells in cancer
Share to Phagocytosis and Immune Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38243698
DOI: 10.1097/cm9.0000000000002944

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a novel HER2-CAR monocyte cell therapy with controllable proliferation and enhanced anti-tumor efficacyPMID 38243698Read ↗

Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptorSemantic proximity Read ↗

A Novel Chimeric Antigen Receptor (CAR) - Strategy to Target EGFR<sup>VIII</sup>-Mutated Glioblastoma Cells via MacrophagesSemantic proximity Read ↗

Harnessing Inflammatory Monocytes to Overcome Resistance to Anti-PD-1 ImmunotherapySemantic proximity Read ↗

CAR-Engineered Human Hematopoietic Stem Cell Macrophages Control Solid TumorsSemantic proximity Read ↗

Macrophages expressing chimeric cytokine receptors have an inflammatory phenotype and anti-tumoral activity upon IL-10 or TGFβ stimulationSemantic proximity Read ↗

An In Vitro Model to Assess CRS Potential of CAR T Cells Using a Tumor Cell Line and Autologous MonocytesSemantic proximity Read ↗

MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9⁺ monocyte-macrophage programming and durable anti-tumor immunity in triple negative breast cancerSemantic proximity Read ↗

Dynamic CD8+ T Cell Cooperation with Macrophages and Monocytes for Successful Cancer ImmunotherapySemantic proximity Read ↗

An in situ generated CAR-M with IFN-γ and negative dominance Sirpα isoform augments hepatocellular carcinoma immunotherapySemantic proximity Read ↗

Interferon-Induced Monocyte Immune Response Augments Immunotherapy and Correlates with Clinical Outcomes in Breast CancerSemantic proximity Read ↗

A novel Chimeric Antigen Receptor (CAR) - strategy to target EGFRVIII-mutated glioblastoma cells via macrophages.Semantic proximity Read ↗

Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.